Jean-Jacques Bienaime, CEO of drugmaker BioMarin, discussed the impact of 340B on pharmaceutical sales during an investor earnings call.
Drugmakers Highlight 340B Developments in Earnings Calls
Pharmaceutical company executives discussed a range of 340B-related developments in recent third quarter investor calls. An executive for BioMarin Pharmaceutical, [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.